Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Background There is uncertainty around clinical applicability of tumor mutational burden (TMB) across cancer types, in part because of inconsistency between TMB measurements from different platforms. The KEYNOTE 158 trial supported United States Food and Drug Administration (FDA) approval of the Fou...

Full description

Saved in:
Bibliographic Details
Main Authors: Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/2/e010311.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/2/e010311.full

Similar Items